Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L3JI
|
|||
| Former ID |
DCL000898
|
|||
| Drug Name |
NGD 94-1
|
|||
| Synonyms |
2-[4-[(2-Phenyl-1H-imidazol-5-yl)methyl]piperazin-1-yl]pyrimidine; Ngd 94-1; 178928-68-2; UNII-DO9M06BFRJ; Ngd-94-1; DO9M06BFRJ; CHEMBL103772; 179333-18-7; 2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]piperazin-1-yl]pyrimidine; 2-[4-[(2-Phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]-pyrimidine; 2-[4-[(2-phenyl-3H-imidazol-4-yl)methyl]piperazin-1-yl]pyrimidine; [3H]NGD941; [3H]-NGD941; [3H]NGD 94-1; AC1L4NQX; ngd94-1; 2-{4-[(2-phenyl-1h-imidazol-4-yl)methyl]piperazin-1-yl}pyrimidine; 2-Phenyl-4(5)-((4-(2-pyrimidinyl)-piperazin-1-yl)methyl)imidazole dimaleate; AC1Q4X5G; GTPL979; SCHEMBL6901339; Ngd-94-1; Diphenylbutylpiperidines pimozide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 1 | [1], [2] | |
| Company |
Schering-Plough
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H20N6
|
|||
| Canonical SMILES |
C1CN(CCN1CC2=CN=C(N2)C3=CC=CC=C3)C4=NC=CC=N4
|
|||
| InChI |
1S/C18H20N6/c1-2-5-15(6-3-1)17-21-13-16(22-17)14-23-9-11-24(12-10-23)18-19-7-4-8-20-18/h1-8,13H,9-12,14H2,(H,21,22)
|
|||
| InChIKey |
OTVQCHUIPJYASM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 178928-68-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980118, 10260910, 14752667, 14801399, 33510547, 47954537, 48404542, 57396204, 79440170, 85209204, 103114526, 103318571, 103857974, 103952294, 113444874, 117522070, 126451647, 128861023, 134339350, 134339963, 135165781, 135650712, 136351236, 137074326, 137111890, 142282999, 143160218, 162805282, 163121853, 172876490, 178100334, 179293732, 204363639, 232578952, 233957622, 241376369, 246752231, 249617821, 252157171
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 979). | |||
| REF 2 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 3 | II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1. J Pharmacol Exp Ther. 1997 Aug;282(2):1020-7. | |||
| REF 4 | Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.